CRNX

Crinetics Pharmaceuticals Inc (CRNX) | Rumor.io

Crinetics Pharmaceuticals

CRNX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,594

Bullish sentiment (50-day avg)29%

Price to earnings ratio-17.2

Market capitalization9B

Earnings per share-5.05

Dividend yield (TTM)—

Revenue (annual)7.7M

Net income (annual)-465.3M

Social

What share of all stock conversation is about CRNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 8

$CRNX, a biotech company, has a strong commercial momentum and is expected to benefit from Vertex's acquisition, which could lead to a significant increase in its stock price.
The acquisition is worth $10 billion, with Vertex paying a 102% premium for Crinetics Pharmaceuticals, indicating a high level of confidence in the company's products, particularly in the area of rare diseases.
Historically, biotechs in a similar setup have raised equity 33% of the time within 90 days, indicating a potential risk of dilution for investors, and they should consider adjusting their positions accordingly.

Generated by AI

Sentiment

Of the messages about CRNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	90.91% +71.59	79.12% -9.63
Bearish	—	0%	9.09% -71.59	20.88% +9.63

Bullish· Jul 7

Crinetics Pharmaceuticals, Inc. (CRNX) has been acquired by Vertex Pharmaceuticals for $85 per share in cash, representing a 102% premium over its previous closing price.
The acquisition validates Crinetics' endocrine blockbuster portfolio, led by its newly launched acromegaly oral drug Palsonify and its late-stage Phase 3 candidate atumelnant.
The deal values Crinetics at $10 billion and is expected to close in Q3 2026, making the stock a pure merger arbitrage play trading just cents below the final cash buyout price.

Bearish· Sep 26

$CRNX's market capitalization and cash reserves may not be sufficient to support its valuation, with a 17% short position and a potential need for short covering.
The stock's price may be artificially suppressed by market makers attempting to facilitate short covering and stop-loss sweeps, with some users predicting a price increase to $48.
The presence of institutional investors and heavy shorts may contribute to a lack of bullish sentiment around FDA approval, potentially leading to a down day or further price declines.

Generated by AI

Topics

Of the messages about CRNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	97.06%	81.46%
Technical Analysis	—	—	2.94%	9.61%
Analysts	—	—	0%	5.84%
Earnings	—	—	0%	1.18%
Macro	—	—	0%	1.91%
Controversies	—	—	0%	0%

Jul 7

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash deal valued at approximately $10 billion, with Crinetics shareholders set to receive $85 per share.
The acquisition represents a 102.24% premium on Crinetics' last close, and the deal is expected to close in Q3 2026.
The acquisition is seen as a validation of Crinetics' endocrine blockbuster portfolio, led by the newly launched acromegaly oral drug Palsonify and their late-stage Phase 3 candidate atumelnant.

Generated by AI

Community

Of the messages about CRNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	86.87%	55.01%
Newcomers	—	0%	13.13%	44.99%

Regulars· Jan 7

The recent public offering of Crinetics Pharmaceuticals has been well-received, with the stock price increasing by 6.29% intraday and a 1.7% gap up.
The company has made progress in advancing its potential neurocrine competitor with fresh data and new funding, potentially positioning itself as a competitor to Neurocrine Biosciences ($NBIX).
The short squeeze dynamics are favorable, with a short ratio of 10.19 and a short float of 16.15%, creating an opportunity for potential price appreciation.

Newcomers· Jan 7

The newcomer is excited about the strong Phase 2 trial data for Crinetics Pharmaceuticals' drug atumelnant, which significantly reduced hormones.
The newcomer notes that Crinetics Pharmaceuticals' new drug PALSONIFY generated over $5 million in preliminary net revenue in its first quarter, exceeding expectations.
The newcomer is watching for a potential move up in the stock price of Crinetics Pharmaceuticals, Inc. ($CRNX) after the initial surge.

Generated by AI

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]

18d agoYahoo Finance

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

21d agoSeeking Alpha

Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion

26d agoInvesting.com

Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ)

27d agoSeeking Alpha

Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.

28d agofinance.yahoo.com

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

28d agoYahoo Finance

Also Discussed

Investors talking about CRNX also mention

#	Name	Attention
1	IDEAYA Biosciences Inc.IDYA	0%-0.01
2	Mineralys Therapeutics, Inc.MLYS	0%+0
3	Immunovant Inc.IMVT	0%0
4	Fortress Biotech, Inc.FBIO	0%0
5	Celcuity Inc.CELC	0%0
6	Nuvalent, Inc.NUVL	0%0
7	Abivax SAABVX	0.01%-0.01
8	Scholar Rock Holding Corporation Common StockSRRK	0%new
9	Ascendis Pharma A/SASND	0%new
10	Vera Therapeutics Inc.VERA	0%new

Crinetics Pharmaceuticals Inc

Healthcare
Biotechnology

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing oral therapies for rare endocrine diseases and endocrine-related tumors. The company’s current portfolio centers on medicines designed to address conditions driven by hormone dysregulation, with a particular emphasis on acromegaly, carcinoid syndrome, and congenital adrenal hyperplasia. Its lead product, PALSONIFY (paltusotine), is an oral selective somatostatin receptor agonist used in endocrine care, while atumelnant is being developed as an investigational therapy for adrenal-related disorders. Based in San Diego, California, Crinetics Pharmaceuticals operates at the intersection of endocrinology and specialty drug development, serving a market that relies on targeted treatments for complex, underserved rare diseases.

Website

Location

6055 Lusk Boulevard

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about CRNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 8

$CRNX, a biotech company, has a strong commercial momentum and is expected to benefit from Vertex's acquisition, which could lead to a significant increase in its stock price.
The acquisition is worth $10 billion, with Vertex paying a 102% premium for Crinetics Pharmaceuticals, indicating a high level of confidence in the company's products, particularly in the area of rare diseases.
Historically, biotechs in a similar setup have raised equity 33% of the time within 90 days, indicating a potential risk of dilution for investors, and they should consider adjusting their positions accordingly.

Generated by AI

Sentiment

Of the messages about CRNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	90.91% +71.59	79.12% -9.63
Bearish	—	0%	9.09% -71.59	20.88% +9.63

Bullish· Jul 7

Crinetics Pharmaceuticals, Inc. (CRNX) has been acquired by Vertex Pharmaceuticals for $85 per share in cash, representing a 102% premium over its previous closing price.
The acquisition validates Crinetics' endocrine blockbuster portfolio, led by its newly launched acromegaly oral drug Palsonify and its late-stage Phase 3 candidate atumelnant.
The deal values Crinetics at $10 billion and is expected to close in Q3 2026, making the stock a pure merger arbitrage play trading just cents below the final cash buyout price.

Bearish· Sep 26

$CRNX's market capitalization and cash reserves may not be sufficient to support its valuation, with a 17% short position and a potential need for short covering.
The stock's price may be artificially suppressed by market makers attempting to facilitate short covering and stop-loss sweeps, with some users predicting a price increase to $48.
The presence of institutional investors and heavy shorts may contribute to a lack of bullish sentiment around FDA approval, potentially leading to a down day or further price declines.

Generated by AI

Topics

Of the messages about CRNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	97.06%	81.46%
Technical Analysis	—	—	2.94%	9.61%
Analysts	—	—	0%	5.84%
Earnings	—	—	0%	1.18%
Macro	—	—	0%	1.91%
Controversies	—	—	0%	0%

Jul 7

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash deal valued at approximately $10 billion, with Crinetics shareholders set to receive $85 per share.
The acquisition represents a 102.24% premium on Crinetics' last close, and the deal is expected to close in Q3 2026.
The acquisition is seen as a validation of Crinetics' endocrine blockbuster portfolio, led by the newly launched acromegaly oral drug Palsonify and their late-stage Phase 3 candidate atumelnant.

Generated by AI

Community

Of the messages about CRNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	86.87%	55.01%
Newcomers	—	0%	13.13%	44.99%

Regulars· Jan 7

The recent public offering of Crinetics Pharmaceuticals has been well-received, with the stock price increasing by 6.29% intraday and a 1.7% gap up.
The company has made progress in advancing its potential neurocrine competitor with fresh data and new funding, potentially positioning itself as a competitor to Neurocrine Biosciences ($NBIX).
The short squeeze dynamics are favorable, with a short ratio of 10.19 and a short float of 16.15%, creating an opportunity for potential price appreciation.

Newcomers· Jan 7

The newcomer is excited about the strong Phase 2 trial data for Crinetics Pharmaceuticals' drug atumelnant, which significantly reduced hormones.
The newcomer notes that Crinetics Pharmaceuticals' new drug PALSONIFY generated over $5 million in preliminary net revenue in its first quarter, exceeding expectations.
The newcomer is watching for a potential move up in the stock price of Crinetics Pharmaceuticals, Inc. ($CRNX) after the initial surge.

Generated by AI

Crinetics Pharmaceuticals

Social

Jul 8

Sentiment

Bullish· Jul 7

Bearish· Sep 26

Topics

Jul 7

Community

Regulars· Jan 7

Newcomers· Jan 7

News

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion

Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ)

Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Also Discussed

Crinetics Pharmaceuticals Inc

Company Information

Location

News

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion

Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ)

Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Also Discussed

Social

Jul 8

Sentiment

Bullish· Jul 7

Bearish· Sep 26

Topics

Jul 7

Community

Regulars· Jan 7

Newcomers· Jan 7